Amalia Colangelo, PhD

Amalia is a Principal at Two Bear Capital, where she leads investments in drug discovery platforms. Before joining the firm, she was a management consultant advising global clients on R&D strategy, antibody-drug conjugate M&A deals, and VC diligence for emerging therapeutics. She has also worked at two life science venture funds, sourcing and evaluating therapeutic and diagnostic investment opportunities. Amalia earned her PhD in Biological and Biomedical Sciences from Harvard University under Dr. Jason Buenrostro in the Department of Stem Cell and Regenerative Biology. Her doctoral research focused on applying single cell genomics and high-throughput imaging technologies to uncover links between epigenetic regulation, cell fate plasticity, and mechanical stress responses. Passionate about global health, Amalia co-founded MyBelle, an NGO dedicated to reducing maternal mortality in Nigeria through mobile clinics, informational seminars, and a maternal-health app. This work led to publications evaluating the World Health Organization’s calcium intake guidelines, highlighting the impact of calcium deficiency on maternal health, and pregnancy-related hypertension.